Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Metabolic Research

Background:

• Hepatocellular carcinoma (HCC) is a prevalent and aggressive cancer with increasing global incidence.
• Current HCC treatments like chemotherapy face limitations such as chemoresistance.
• Tumor development is significantly influenced by metabolic reprogramming, particularly in liver cancer.

Purpose of the Study:

• To review pharmaceutical interventions targeting metabolic pathways in HCC.
• To highlight key metabolic targets in glucose, fatty acid, amino acid, and glutamine metabolism for HCC therapy.
• To discuss current agents and future opportunities in developing metabolism-targeted HCC treatments.

Main Methods:

• Literature review of pharmaceutical therapies for HCC.
• Analysis of metabolic reprogramming in HCC pathogenesis.
• Summary of current research on agents targeting deregulated metabolism in HCC.

Main Results:

• Metabolic pathways, including glucose, fatty acid, amino acid, and glutamine metabolism, are crucial in HCC.
• Abnormal metabolism presents viable targets for novel pharmaceutical interventions in HCC.
• Existing studies show promise in targeting deregulated metabolism for HCC treatment.

Conclusions:

• Targeting aberrant metabolism represents a promising therapeutic avenue for hepatocellular carcinoma.
• Further research into metabolic targets and agents is essential for advancing HCC treatment strategies.
• Addressing metabolic dysregulation may overcome limitations of current HCC therapies, such as chemoresistance.